| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $4.74B | +15.2% |
| Cost of Revenue | $2.66B | +15.4% |
| Gross Profit | $2.07B | +14.9% |
| R&D Expense | $729.5M | +1.3% |
| SG&A Expense | $386.2M | +4.1% |
| Operating Income | -$5.6M | +97.4% |
| Pre-tax Income | $93.9M | +178.3% |
| Income Tax | $5.5M | -41.3% |
| Net Income | $88.4M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.59B | -26.5% |
| Short-term Investments | $730.2M | — |
| Accounts Receivable | $879.9M | +8.3% |
| Inventory | $114.6M | -27.6% |
| Current Assets | $3.40B | +5.2% |
| Total Assets | $4.43B | +3.0% |
| Current Liabilities | $1.24B | +0.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $483.7M | +121.8% |
| Capital Expenditures | $5.3M | +4.3% |
| Investing Cash Flow | -$782.4M | -3021.9% |
| Financing Cash Flow | -$280.1M | -214.0% |
| Free Cash Flow | $478.4M | +124.6% |
| +168.3% |
| EPS (Basic) | $0.60 | +167.4% |
| EPS (Diluted) | $0.59 | +166.3% |
| Total Liabilities |
| $1.78B |
| -2.0% |
| Stockholders' Equity | $2.66B | +6.6% |